MDMA-assisted therapy is being evaluated in Phase II and III trials, primarily for post-traumatic stress disorder (PTSD) and social anxiety.
| Trial | Drug | Phase | Status | Sponsor | Conditions | Start date |
|---|---|---|---|---|---|---|
| MDMA-AT for PTSD in Young Adults With Childhood Trauma | MDMA | Phase 2 | Not Yet Recruiting | Jenna M. Traynor | Posttraumatic Stress Disorder (PTSD) | Oct 31, 2026 |
| MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders | MDMA | Phase 2 | Not Yet Recruiting | Nautilus Sanctuary | Post-Traumatic Stress Disorder, Adjustment Disorders | Oct 1, 2026 |
| MDMA-assisted Therapy for Fibromyalgia | MDMA | Early Phase 1 | Recruiting | Spaulding Rehabilitation Hospital | Fibromyalgia | Sep 15, 2026 |
| MDMA-Assisted Massed Exposure Therapy for PTSD | MDMA | Phase 2 | Recruiting | Emory University | Post Traumatic Stress Disorder | Jul 1, 2026 |
| MDMA Therapy in Veterans With PTSD | MDMA | Phase 2 | Recruiting | Sunstone Medical | Post Traumatic Stress Disorder | Jun 30, 2026 |
| MDMA Assisted Therapy for BN | MDMA | Phase 1 | Recruiting | Icahn School of Medicine at Mount Sinai | Bulimia Nervosa | May 22, 2026 |
| MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder | MDMA | Phase 2 / Phase 3 | Recruiting | VA Office of Research and Development | Post Traumatic Stress Disorder, Alcohol Use Disorder | May 18, 2026 |
| Study of Midomafetamine in Healthy Adults | MDMA | Phase 1 | Active Not Recruiting | Resilient Pharmaceuticals | Healthy Volunteers | Apr 23, 2026 |
| MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function | MDMA | Phase 1 | Not Yet Recruiting | Resilient Pharmaceuticals | Pharmacokinetics, Hepatic Impairment | Mar 29, 2026 |
| MDMA-Assisted Therapy for Mental Healthcare Providers | MDMA | Phase 1 | Recruiting | Rachel Yehuda | Mental Wellbeing | Feb 11, 2026 |
| MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) | MDMA | Phase 2 | Recruiting | Carolyn Rodriguez | Obsessive-Compulsive Disorder | Sep 10, 2025 |
| MDMA in Borderline Personality Disorder | MDMA | Phase 2 | Recruiting | Yale University | Borderline Personality Disorder | Sep 5, 2025 |
| MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents | MDMA | Phase 2 | Withdrawn | University of California, Los Angeles | PTSD, Post Traumatic Stress Disorder, Adolescents, Psychotherapy | Jul 1, 2025 |
| Dose Optimization of MDMA-Assisted Therapy for PTSD | MDMA | Phase 2 | Recruiting | Bronx VA Medical Center | Posttraumatic Stress Disorder | Jun 3, 2025 |
| MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder | MDMA | Phase 2 | Recruiting | Stephen Robert Marder | Post Traumatic Stress Disorder | Mar 1, 2025 |
| MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder | MDMA | Phase 2 | Recruiting | Patricia Suppes | PTSD | Feb 10, 2025 |
| MDMA-assisted Massed Prolonged Exposure for PTSD | MDMA | Phase 3 | Active Not Recruiting | Healing Breakthrough | Post-Traumatic Stress Disorder | Oct 25, 2024 |
| Tolerability of MDMA in Schizophrenia | MDMA | Phase 1 / Phase 2 | Recruiting | Anya Bershad, MD, PhD | Schizophrenia | Sep 1, 2024 |
| MDMA-Assisted Therapy for Pathological Narcissism | MDMA | Early Phase 1 | Active Not Recruiting | University of Washington | Narcissism | Aug 27, 2024 |
| The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD. | MDMA | Phase 1 | Withdrawn | Yale University | Post Traumatic Stress Disorder | May 1, 2024 |
| MDMA Plus Exposure Therapy for PTSD | MDMA | Phase 2 | Enrolling By Invitation | Emory University | PTSD | Feb 13, 2024 |
| MDMA for AUD/PTSD Comorbidity | MDMA | Phase 2 | Completed | Carolina L Haass-Koffler | Alcohol Use Disorder, Post Traumatic Stress Disorder | Feb 6, 2024 |
| MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD | MDMA | Phase 3 | Completed | Dr. Leslie Morland | PTSD, Relational Problems | Oct 6, 2023 |
| Group MDMA-therapy for Veterans With PTSD | MDMA | Phase 1 / Phase 2 | Completed | Portland VA Research Foundation, Inc | PTSD | Oct 1, 2023 |
| Prosocial Effects of MDMA | MDMA | Early Phase 1 | Completed | University of Chicago | MDMA ('Ecstasy'), Social Interaction | Jul 21, 2023 |
| MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other | MDMA | Phase 2 | Recruiting | Sunstone Medical | Cancer, Adjustment Disorders | Oct 6, 2022 |
| Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD | MDMA | N/A | Completed | Albany Research Institute, Inc. | Post Traumatic Stress Disorder | Aug 8, 2022 |
| Food Effects on Bioavailability of MDMA in Healthy Volunteers | MDMA | Phase 1 | Completed | Resilient Pharmaceuticals | Pharmacokinetics | Jul 28, 2022 |
| Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function | MDMA | Early Phase 1 | Completed | University of Chicago | Stimulant Use, MDMA ('Ecstasy'), Social Behavior, Motivation | May 11, 2022 |
| Social Anxiety MDMA-Assisted Therapy Investigation | MDMA | Phase 2 | Completed | Jason B Luoma | Social Anxiety Disorder | Apr 13, 2022 |
| Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy | MDMA | N/A | Unknown | Apollo Neuroscience, Inc. | Stress Disorders, Post-Traumatic | Dec 8, 2021 |
| Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD | MDMA | Phase 2 | Terminated | Resilient Pharmaceuticals | PTSD | Nov 8, 2021 |
| Stanford Regulating Circuits of the Brain Study - MDMA | MDMA | N/A | Completed | Stanford University | Healthy | Nov 2, 2021 |
| Drug Effects on Interpersonal Interaction | MDMA | Early Phase 1 | Completed | University of Chicago | Interaction, Social | Aug 1, 2021 |
| MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD | MDMA | Phase 2 | Completed | VA Loma Linda Health Care System | Post Traumatic Stress Disorder, Combat Stress Disorders | Jul 29, 2021 |
| A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD | MDMA | Phase 3 | Completed | Resilient Pharmaceuticals | PTSD | Mar 8, 2021 |
| Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD | MDMA | N/A | Completed | Resilient Pharmaceuticals | PTSD | Mar 1, 2021 |
| A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2) | MDMA | Phase 3 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Sep 2, 2020 |
| A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1) | MDMA | Phase 3 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Nov 21, 2018 |
| Epigenetics and MDMA-Assisted Psychotherapy for PTSD | MDMA | Phase 3 | Completed | University of Southern California | PTSD | Nov 20, 2018 |
| Effects of an 8-day Advanced Meditation, Samyama on Physical, Psychological and Spiritual Wellbeing ,and Associated Neural Mechanisms | MDMA | N/A | Completed | Indiana University | Mental Health Wellness 1, Happiness, Depression, Consciousness, Level Altered, Ecstasy, Dietary Habits, Stress, Inflammatory Bowel Diseases | Jan 19, 2018 |
| Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD | MDMA | Phase 2 | Completed | Resilient Pharmaceuticals | PTSD | Nov 16, 2017 |
| Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT) | MDMA | Phase 2 | Terminated | Eagle Pharmaceuticals, Inc. | Drug Toxicity Psychotropic Agents Psychostimulants | Aug 12, 2017 |
| Evaluation of MDMA on Startle Response | MDMA | Phase 1 | Completed | Resilient Pharmaceuticals | Startle Response | Mar 14, 2017 |
| MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD | MDMA | Phase 1 / Phase 2 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Jul 3, 2016 |
| Effect of Stimulant Drugs on Social Perception | MDMA | Phase 1 | Completed | University of Chicago | Healthy, MDMA ('Ecstasy') | Jun 1, 2016 |
| Correlates of Anxiety Associated With a Life-threatening Illness | MDMA | N/A | Completed | Resilient Pharmaceuticals | Anxiety | Nov 7, 2015 |
| MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness | MDMA | Phase 2 | Completed | Resilient Pharmaceuticals | Anxiety | May 14, 2015 |
| Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults | MDMA | Phase 2 | Completed | Resilient Pharmaceuticals | Social Anxiety in Autistic Adults | Apr 11, 2014 |
| Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD | MDMA | N/A | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Jan 1, 2014 |
| Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD | MDMA | Phase 2 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | May 13, 2013 |
| Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers | MDMA | Phase 1 | Completed | Resilient Pharmaceuticals | Psychological Effects of Study Drug | Apr 9, 2011 |
| Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial | MDMA | Phase 2 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Dec 15, 2010 |
| Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder | MDMA | Phase 2 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Nov 10, 2010 |
| Effects of MDMA on Social and Emotional Processing | MDMA | N/A | Completed | University of Chicago | Drug Addiction | Jul 1, 2010 |
| Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition. | MDMA | N/A | Completed | California Pacific Medical Center Research Institute | MDMA Discontinuation Syndrome | Apr 1, 2010 |
| Role of Serotonin in Acute and Subacute MDMA Effects | MDMA | N/A | Completed | California Pacific Medical Center Research Institute | MDMA Mechanism of Action | Feb 1, 2009 |
| MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer | MDMA | Phase 2 | Terminated | Brigham and Women's Hospital | Anxiety Disorder, Cancer | Feb 1, 2007 |
| MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder | MDMA | Phase 2 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Mar 12, 2004 |
| A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD | MDMA | N/A | No Longer Available | Resilient Pharmaceuticals | Post Traumatic Stress Disorder | |
| Neurobiology and Pharmacokinets of Acute MDMA Administration | MDMA | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | Substance-Related Disorders | Feb 10, 2004 |
All psychedelic clinical trials · Psilocybin clinical trials
MDMA-assisted therapy is studied primarily for post-traumatic stress disorder, along with social anxiety in autistic adults, eating disorders, and anxiety related to life-threatening illness.
MDMA research for PTSD has completed Phase III trials, making it one of the most advanced psychedelic treatment programs. Additional Phase I and Phase II studies continue for other indications.
No. MDMA remains a Schedule I substance and is not approved for prescription use. It is available only through authorized clinical research or expanded access programs.
Each trial listing links to its ClinicalTrials.gov record with eligibility criteria and site contacts. Screening and enrollment are handled directly by the study sponsor and its investigators.
In trials, MDMA is given in a small number of supervised dosing sessions paired with preparatory and integrative psychotherapy, rather than as a daily take-home medication.